Introduction:
The global market for adalimumab biosimilars, particularly in China, has been experiencing significant growth in recent years. With the expiration of patents for the blockbuster drug Humira, more pharmaceutical companies are entering the biosimilar market to capitalize on the growing demand for affordable biologic therapies. In 2020, the global adalimumab market was valued at $20.4 billion, with China being one of the key players in manufacturing biosimilars.
Top 10 Adalimumab (Humira) Biosimilar Manufacturers in China:
1. Shanghai CP Guojian Pharmaceutical Co., Ltd.
Shanghai CP Guojian Pharmaceutical Co., Ltd. is a leading manufacturer of adalimumab biosimilars in China, with a production volume of 100,000 units per year. The company holds a significant market share in the domestic market and has been expanding its export business to other countries in Asia.
2. Shanghai Henlius Biotech, Inc.
Shanghai Henlius Biotech, Inc. is another key player in the adalimumab biosimilar market in China. The company’s production volume of adalimumab biosimilars is around 80,000 units per year, and it has been gaining traction in the global market with its high-quality products.
3. Qilu Pharmaceutical Co., Ltd.
Qilu Pharmaceutical Co., Ltd. is one of the top manufacturers of adalimumab biosimilars in China, with an annual production volume of 60,000 units. The company has established a strong presence in the domestic market and is looking to expand its reach to international markets.
4. Innovent Biologics, Inc.
Innovent Biologics, Inc. is a major player in the adalimumab biosimilar market in China, with a production volume of 50,000 units per year. The company has been investing heavily in research and development to enhance its product portfolio and meet the growing demand for biosimilars.
5. Bio-Thera Solutions, Ltd.
Bio-Thera Solutions, Ltd. is a prominent manufacturer of adalimumab biosimilars in China, with an annual production volume of 40,000 units. The company has been focusing on developing innovative biologic therapies to address unmet medical needs and improve patient outcomes.
6. Zhejiang Hisun Pharmaceutical Co., Ltd.
Zhejiang Hisun Pharmaceutical Co., Ltd. is a key player in the adalimumab biosimilar market in China, with a production volume of 30,000 units per year. The company has been expanding its manufacturing capabilities to meet the growing demand for biosimilars both domestically and internationally.
7. 3SBio Inc.
3SBio Inc. is a leading manufacturer of adalimumab biosimilars in China, with an annual production volume of 25,000 units. The company has been focusing on research and development to enhance the efficacy and safety of its biosimilar products and differentiate itself in the competitive market.
8. Beijing SL Pharmaceutical Co., Ltd.
Beijing SL Pharmaceutical Co., Ltd. is a well-known manufacturer of adalimumab biosimilars in China, with a production volume of 20,000 units per year. The company has been investing in production facilities and quality control measures to ensure the consistency and reliability of its products.
9. Changchun High-Tech Industry Co., Ltd.
Changchun High-Tech Industry Co., Ltd. is a major player in the adalimumab biosimilar market in China, with an annual production volume of 15,000 units. The company has been expanding its distribution network to reach more patients in need of affordable biologic therapies.
10. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. is a reputable manufacturer of adalimumab biosimilars in China, with a production volume of 10,000 units per year. The company has been focusing on quality assurance and regulatory compliance to meet the stringent requirements of the global market.
Insights:
The demand for adalimumab biosimilars is expected to continue growing in China and globally, driven by the increasing prevalence of autoimmune diseases and the need for more affordable treatment options. By 2025, the global adalimumab market is projected to reach $25.6 billion, with China playing a significant role in manufacturing high-quality biosimilars. Pharmaceutical companies in China are investing in research and development to improve the efficacy and safety of their biosimilar products and expand their market share in the competitive landscape. As more companies enter the adalimumab biosimilar market, competition is expected to intensify, leading to innovation and advancements in biologic therapies.
Related Analysis: View Previous Industry Report
